↓ Skip to main content

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

Overview of attention for article published in Frontiers in oncology, November 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
4 X users

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
Published in
Frontiers in oncology, November 2022
DOI 10.3389/fonc.2022.951267
Pubmed ID
Authors

Gretchen Bergado-Báez, Narjara Gonzalez Suarez, Lisset Chao García, Dayana Pérez-Martínez, Diana Rosa Hernández-Fernández, Talia Fundora-Barrios, Antonio Rodríguez-Álvarez, Geidy Diana Díaz-Ordaz, Moshit Lindzen, Yosef Yarden, Belinda Sánchez-Ramírez

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer > Senior Lecturer 1 17%
Professor 1 17%
Unknown 4 67%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 17%
Agricultural and Biological Sciences 1 17%
Unknown 4 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#16,562,997
of 26,580,681 outputs
Outputs from Frontiers in oncology
#5,310
of 23,319 outputs
Outputs of similar age
#217,264
of 448,377 outputs
Outputs of similar age from Frontiers in oncology
#403
of 1,716 outputs
Altmetric has tracked 26,580,681 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 23,319 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,377 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,716 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.